BLACKROCK ESG CAP ALL TRM TR (ECAT) Fundamental Analysis & Valuation

NYSE:ECAT • US09262F1003

14.57 USD
-0.02 (-0.14%)
At close: Mar 9, 2026
14.61 USD
+0.04 (+0.27%)
After Hours: 3/9/2026, 8:04:00 PM
Overview Stock Chart Technical Analysis News

This ECAT fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

Overall ECAT gets a fundamental rating of 2 out of 10. We evaluated ECAT against 0 industry peers in the Unkown industry. ECAT may be in some trouble as it scores bad on both profitability and health. ECAT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. ECAT Profitability Analysis

1.1 Basic Checks

  • ECAT had positive earnings in the past year.
  • In the past year ECAT had a positive cash flow from operations.
ECAT Yearly Net Income VS EBIT VS OCF VS FCFECAT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 -500M -1B -1.5B -2B

1.2 Ratios

  • The last Return On Invested Capital (1.35%) for ECAT is above the 3 year average (1.31%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 8.5%
ROE 9.29%
ROIC 1.35%
ROA(3y)4.06%
ROA(5y)N/A
ROE(3y)3.82%
ROE(5y)N/A
ROIC(3y)1.31%
ROIC(5y)N/A
ECAT Yearly ROA, ROE, ROICECAT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 10 -10

1.3 Margins

  • In the last couple of years the Profit Margin of ECAT has declined.
Industry RankSector Rank
OM 52.96%
PM (TTM) 285.19%
GM 59.26%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-48.47%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ECAT Yearly Profit, Operating, Gross MarginsECAT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 0 1K 2K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. ECAT Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, ECAT has less shares outstanding
  • ECAT has a better debt/assets ratio than last year.
ECAT Yearly Shares OutstandingECAT Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 20M 40M 60M 80M 100M
ECAT Yearly Total Debt VS Total AssetsECAT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

  • ECAT has an Altman-Z score of 5.62. This indicates that ECAT is financially healthy and has little risk of bankruptcy at the moment.
  • ECAT has a debt to FCF ratio of 0.01. This is a very positive value and a sign of high solvency as it would only need 0.01 years to pay back of all of its debts.
  • ECAT has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
  • Even though the debt/equity ratio score it not favorable for ECAT, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.01
Altman-Z 5.62
ROIC/WACCN/A
WACCN/A
ECAT Yearly LT Debt VS Equity VS FCFECAT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 1B -1B 2B -2B

2.3 Liquidity

  • A Current Ratio of 0.05 indicates that ECAT may have some problems paying its short term obligations.
  • ECAT has a Quick Ratio of 0.05. This is a bad value and indicates that ECAT is not financially healthy enough and could expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 0.05
Quick Ratio 0.05
ECAT Yearly Current Assets VS Current LiabilitesECAT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. ECAT Growth Analysis

3.1 Past

  • The earnings per share for ECAT have decreased strongly by -40.23% in the last year.
  • Measured over the past years, ECAT shows a very strong growth in Earnings Per Share. The EPS has been growing by 45.23% on average per year.
  • ECAT shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -13.09%.
  • ECAT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 175.73% yearly.
EPS 1Y (TTM)-40.23%
EPS 3Y45.23%
EPS 5YN/A
EPS Q2Q%-47.46%
Revenue 1Y (TTM)-13.09%
Revenue growth 3Y175.73%
Revenue growth 5YN/A
Sales Q2Q%-23.53%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ECAT Yearly Revenue VS EstimatesECAT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 20M 40M 60M

More info and screens

Find the best growth stocksShow best growing peers

1

4. ECAT Valuation Analysis

4.1 Price/Earnings Ratio

  • ECAT is valuated reasonably with a Price/Earnings ratio of 9.34.
  • ECAT's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.46.
Industry RankSector Rank
PE 9.34
Fwd PE N/A
ECAT Price Earnings VS Forward Price EarningsECAT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF 3.56
EV/EBITDA N/A
ECAT Per share dataECAT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. ECAT Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 21.10%, ECAT is a good candidate for dividend investing.
  • ECAT's Dividend Yield is rather good when compared to the S&P500 average which is at 1.82.
Industry RankSector Rank
Dividend Yield 21.1%

5.2 History

  • ECAT has been paying a dividend for over 5 years, so it has already some track record.
  • ECAT has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)N/A
Div Incr Years3
Div Non Decr Years3
ECAT Yearly Dividends per shareECAT Yearly Dividends per shareYearly Dividends per share 2021 2022 2023 2024 2025 2026 1 2 3

5.3 Sustainability

  • 235.71% of the earnings are spent on dividend by ECAT. This is not a sustainable payout ratio.
DP235.71%
EPS Next 2YN/A
EPS Next 3YN/A
ECAT Yearly Income VS Free CF VS DividendECAT Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2021 2022 2023 2024 0 -500M -1B -1.5B -2B
ECAT Dividend Payout.ECAT Dividend Payout, showing the Payout Ratio.ECAT Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

ECAT Fundamentals: All Metrics, Ratios and Statistics

BLACKROCK ESG CAP ALL TRM TR

NYSE:ECAT (3/9/2026, 8:04:00 PM)

After market: 14.61 +0.04 (+0.27%)

14.57

-0.02 (-0.14%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)03-02
Earnings (Next)N/A
Inst Owners37.87%
Inst Owner Change-2.55%
Ins Owners0%
Ins Owner Change0%
Market Cap1.45B
Revenue(TTM)54.00M
Net Income(TTM)154.00M
Analysts0
Price TargetN/A
Short Float %0.16%
Short Ratio0.32
Dividend
Industry RankSector Rank
Dividend Yield 21.1%
Yearly Dividend2.87
Dividend Growth(5Y)N/A
DP235.71%
Div Incr Years3
Div Non Decr Years3
Ex-Date06-15
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 9.34
Fwd PE N/A
P/S 26.81
P/FCF 3.56
P/OCF 3.56
P/B 0.87
P/tB 0.87
EV/EBITDA N/A
EPS(TTM)1.56
EY10.71%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)4.1
FCFY28.12%
OCF(TTM)4.1
OCFY28.12%
SpS0.54
BVpS16.67
TBVpS16.67
PEG (NY)N/A
PEG (5Y)N/A
Graham Number24.19
Profitability
Industry RankSector Rank
ROA 8.5%
ROE 9.29%
ROCE 1.71%
ROIC 1.35%
ROICexc 1.35%
ROICexgc 1.35%
OM 52.96%
PM (TTM) 285.19%
GM 59.26%
FCFM 753.7%
ROA(3y)4.06%
ROA(5y)N/A
ROE(3y)3.82%
ROE(5y)N/A
ROIC(3y)1.31%
ROIC(5y)N/A
ROICexc(3y)1.31%
ROICexc(5y)N/A
ROICexgc(3y)1.34%
ROICexgc(5y)N/A
ROCE(3y)1.67%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-48.47%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.01
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 250
Cash Conversion N/A
Profit Quality 264.29%
Current Ratio 0.05
Quick Ratio 0.05
Altman-Z 5.62
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-40.23%
EPS 3Y45.23%
EPS 5YN/A
EPS Q2Q%-47.46%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-13.09%
Revenue growth 3Y175.73%
Revenue growth 5YN/A
Sales Q2Q%-23.53%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-21.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y128.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y128.78%
OCF growth 3YN/A
OCF growth 5YN/A

BLACKROCK ESG CAP ALL TRM TR / ECAT FAQ

Can you provide the ChartMill fundamental rating for BLACKROCK ESG CAP ALL TRM TR?

ChartMill assigns a fundamental rating of 2 / 10 to ECAT.


What is the valuation status for ECAT stock?

ChartMill assigns a valuation rating of 1 / 10 to BLACKROCK ESG CAP ALL TRM TR (ECAT). This can be considered as Overvalued.


Can you provide the profitability details for BLACKROCK ESG CAP ALL TRM TR?

BLACKROCK ESG CAP ALL TRM TR (ECAT) has a profitability rating of 1 / 10.


What are the PE and PB ratios of BLACKROCK ESG CAP ALL TRM TR (ECAT) stock?

The Price/Earnings (PE) ratio for BLACKROCK ESG CAP ALL TRM TR (ECAT) is 9.34 and the Price/Book (PB) ratio is 0.87.


How financially healthy is BLACKROCK ESG CAP ALL TRM TR?

The financial health rating of BLACKROCK ESG CAP ALL TRM TR (ECAT) is 3 / 10.